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Cortistatin, a new antiinfl  ammatory peptide 
with therapeutic eff  ect on lethal endotoxemia
Elena Gonzalez-Rey, Alejo Chorny, Gema Robledo, and Mario Delgado
Institute of Parasitology and Biomedicine, Consejo Superior de Investigaciones Cientifi  cas, Granada 18100, Spain
Cortistatin is a recently discovered cyclic neuropeptide related to somatostatin that has 
emerged as a potential endogenous antiinfl  ammatory factor based on its production by and 
binding to immune cells. Because human septic shock involves excessive infl  ammatory 
cytokine production, we investigated the effect of cortistatin on the production of infl  am-
matory mediators and its therapeutic action in various murine models of endotoxemia. 
Cortistatin down-regulated the production of infl  ammatory mediators by endotoxin-
activated macrophages. The administration of cortistatin protected against lethality after 
cecal ligation and puncture, or injection of bacterial endotoxin or Escherichia coli, and 
prevented the septic shock-associated histopathology, such as infi  ltration of infl  ammatory 
cells and intravascular disseminated coagulation in various target organs. The therapeutic 
effect of cortistatin was mediated by decreasing the local and systemic levels of a wide 
spectrum of infl  ammatory mediators, including cytokines, chemokines, and acute phase 
proteins. The combined use of cortistatin and other antiinfl  ammatory peptides was very 
effi  cient treating murine septic shock. This work provides the fi  rst evidence of cortistatin 
as a new immunomodulatory factor with the capacity to deactivate the infl  ammatory 
response. Cortistatin represents a potential multistep therapeutic agent for human septic 
shock, to be used in combination with other immunomodulatory agents or as a complement 
to other therapies.
Septic shock is a systemic response to se-
vere bacterial infections, generally caused by 
Gram-negative bacterial endotoxins. Indeed, 
the administration of the endotoxin LPS to 
experimental animals leads to pathophysi-
ologic changes similar to human septic shock 
syndrome, and lethal endotoxemia has been 
extensively used as an experimental model of 
Gram-negative septic shock (1). The septic 
shock syndrome is characterized by a hyper-
active and out-of-balance network of endog-
enous proinfl  ammatory cytokines, including 
TNFα, IL-12, IL-6, and IFNγ (2). The over-
production of infl  ammatory cytokines gener-
ates systemic activation, which aff  ects vascular 
permeability and cardiac function and induces 
metabolic changes that can lead to tissue ne-
crosis and eventually to multiple-organ failure and 
death. The current therapeutic strategies for 
human septic shock are designed to neutralize 
one or more of the infl  ammatory mediators, 
and none of them are entirely eff  ective (3, 4). 
This illustrates the need for novel therapeutic 
approaches to down-regulate the exacerbated 
infl  ammatory response typical of endotoxemia.
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Cortistatin is a recently discovered cyclic 
neuropeptide named after its predominantly 
cortical expression and ability to depress corti-
cal activity (5). Cortistatin shows a high ho-
mology with somatostatin; however, based on 
nucleotide sequence and chromosomal loca-
tion, they are products of separate genes. Cor-
tistatin binds to all fi   ve cloned somatostatin 
receptors and shares many pharmacological and 
functional properties with somatostatin, in-
cluding the depression of neuronal activity and 
inhibition of cell proliferation (6). However, 
cortistatin also has many distinct properties, in-
cluding induction of slow-wave sleep and re-
duction of locomotor activity (6). Cortistatin, 
but not somatostatin, has been detected in vari-
ous human immune cells, including lympho-
cytes, monocytes, macrophages, and dendritic 
cells (7–9). Therefore, some of the somatosta-
tin immunomodulatory actions could be shared 
by cortistatin. Because cortistatin levels corre-
late with the degree of infl  ammatory cell dif-
ferentiation and activation (7, 8), this peptide 
could function as a major endogenous regula-
tory factor in the immune system. In addition 564  THERAPEUTIC EFFECT OF CORTISTATIN ON ENDOTOXEMIA | Gonzalez-Rey et al.
to   somatostatin receptors, cortistatin can bind to other hor-
mone receptors that mediate antiinfl  ammatory actions, such 
as the receptor for the growth hormone secretagogue ghrelin 
(10–12). The aim of this study is to investigate the potential 
antiinfl  ammatory action of cortistatin and its therapeutic use 
in murine models of lethal endotoxemia.
RESULTS
Cortistatin inhibits production of infl  ammatory mediators 
by activated macrophages in vitro
Macrophages, major participants in innate immunity, con-
tribute to the initiation of the infl  ammatory response by 
killing pathogens through phagocytosis, release of cytotoxic 
oxygen and nitrogen intermediates, and release of chemo-
kine and cytokines that attract and activate other immune 
cells. Despite the benefi  cial role of infl  ammatory factors in 
host defense, their sustained production can lead to seri-
ous pathological conditions. Therefore, although necessary 
for the elimination of pathogens, macrophage activation 
leads to serious deleterious eff  ects in the host if left un-
checked. To investigate the potential antiinfl  ammatory ac-
tion of cortistatin, we evaluated fi  rst the eff  ect of cortistatin 
on the production of several infl   ammatory mediators by 
peritoneal macrophages. Cortistatin inhibited the produc-
tion of TNFα, IL-6, and nitric oxide (NO) by activated 
macrophages (Fig. 1 A). This eff  ect was dose dependent 
with a maximal eff  ect at 10−8 M (Fig. 1 B), a concentra-
tion that is within the physiological range (6). Interestingly, 
cortistatin showed higher inhibitory eff  ect on TNFα, IL-6, 
and NO production than the structurally related peptide so-
matostatin, or the somatostatin receptor agonist octreotide 
(Fig. 1 B). In addition, although the somatostatin receptor 
antagonist cyclosomatostatin fully blocked the eff  ect of so-
matostatin, it only partially reversed the inhibitory eff  ect of 
cortistatin (Fig. 1 C), suggesting that cortistatin could exert 
its eff   ects through both somatostatin receptor-dependent 
and -independent mechanisms.
Treatment with cortistatin protects against lethal 
endotoxemia and reduces the related histopathology
Because cortistatin inhibits the production of proinfl  am-
matory macrophage-derived factors crucial for the devel-
opment of septic shock, we expected a protective eff  ect in 
high-dose endotoxemia, a murine model for septic shock 
syndrome. Mice were injected with diff  erent doses of LPS, 
treated 30 min later with cortistatin (2 nmol/mouse; 250 
μg/kg), and the survival was monitored. Treatment with 
cortistatin signifi  cantly protected against the lethal eff  ect of 
LPS (Fig. 2 A). The protective eff  ect was observed over a 
wide range of LPS doses, with cortistatin shifting the LD50 
from 100 to 450 μg LPS (Fig. 2 B). Animals injected with 
cortistatin had a survival rate of 80%; even for the nonsur-
vivors, cortistatin doubled the time until death (Fig. 2 C). 
The eff  ect of cortistatin was dose dependent, with doses 
as low as 0.5 nmol (50 μg/kg) being partially protective 
(Fig. 2 D). In contrast, somatostatin and octreotide, or the 
control peptide cyclosomatostatin were not protective (Fig. 
2 E). Because the production of infl  ammatory cytokines 
occurs in a rapid sequence starting with TNFα, which 
reaches a maximum 2 h after LPS infusion (see Fig. 5), 
we next investigated the therapeutic eff  ect of cortistatin in 
conditions of already established septic shock. Kinetic stud-
ies showed that cortistatin exerted a full protective   action 
Figure 1.  Cortistatin inhibits the production of infl  ammatory me-
diators by activated macrophages in vitro. (A) Peritoneal macrophages 
were stimulated with 1 μg/ml LPS in the absence (control) or presence of 
10−8 M cortistatin. After different times, proinfl  ammatory mediators were 
determined (n = 6). *, P < 0.001 versus untreated control mice. (B) Peri-
toneal macrophages were stimulated with 1 μg/ml LPS in the absence 
(control) or presence of different concentrations of cortistatin, soma-
tostatin, octreotide, or cyclosomatostatin. After 24 h, proinfl  ammatory 
mediators were determined (n = 5). *, P < 0.001, #, P < 0.05 versus un-
treated control mice. (C) Peritoneal macrophages were stimulated with 
1 μg/ml LPS and treated with cortistatin, somatostatin, or octreotide 
(10−8 M) in the presence of different concentrations of the antagonist 
cyclosomatostatin (n = 4). Results show the percentage of inhibition of 
cytokine/NO production in comparison to LPS-treated controls.JEM VOL. 203, March 20, 2006  565
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when given up to 4 h after shock   induction (Fig. 2 F), 
with decreased protection for later cortistatin administra-
tion (not depicted).
Endotoxemic animals suff   ered from disseminated in-
travascular coagulation with multiple organ failure as indi-
cated by severe congestion, hemorrhage, hyperemia, fi  brin 
deposits, edema, thrombosis, and massive accumulation of 
leukocytes in lungs and the intestinal tract, as well as severe 
congestion of the hepatic sinusoids, hepatocyte necrosis, 
segmental ischemia of the bowel with regions of hemor-
rhage or necrosis, and an infracted cecum (Fig. 3 A and not 
depicted). Neutrophil infi  ltration in the liver, lungs, and 
intestine of endotoxemic animals was confi  rmed through 
measurements of the myeloperoxidase (MPO) activity (Fig. 
3 B). Endotoxic shock induction was accompanied by an 
early granulocyte (mainly neutrophils) infi   ltration in the 
peritoneum, followed by later recruitment of macrophages 
and lymphocytes (Fig. 3 C). In contrast, cortistatin-treated 
animals did not present any of the histopathologic alterations 
associated with septic shock, such as disseminated intravas-
cular coagulation, leukocyte infi  ltration, and infl  ammation 
in various organs and mesenteric ischemia, tissue conges-
tion, and hemorrhage (Fig. 3).
Cortistatin improves survival in experimental sepsis
We next investigated the potential therapeutic eff  ect of cor-
tistatin in the murine model of cecal ligation and puncture 
(CLP), a clinically relevant model for human sepsis because it 
causes lethal peritonitis produced by polymicrobial infection. 
Cortistatin treatment was started 4 h after the induction 
of sepsis, at a time when mice show clear signs of sepsis, in-
cluding lethargy, piloerection, diarrhea, huddling, fever, and 
  malaise. Cortistatin treatment signifi  cantly improved survival 
(Fig. 4 A), and attenuated the clinical manifestations of sepsis, 
such as lethargy, diarrhea, body weight loss, and hypothermia 
(not depicted). We also examined whether delayed cortistatin 
treatment protects mice against sepsis induced by direct i.p. 
injection of live Escherichia coli. The mortality induced by in-
jection of 108 live E. coli cells was decreased by cortistatin 
(Fig. 4 B). In both models, we did not observe any late deaths 
(up to 3 wk), indicating that cortistatin treatment confers 
  lasting protection.
Cortistatin treatment reduces local and systemic 
infl  ammatory responses in endotoxemic mice
We next evaluated the eff  ect of cortistatin treatment on 
the production of infl  ammatory mediators that are mecha-
nistically linked to endotoxemia. Cortistatin administration 
reduced the levels of endotoxin-induced infl  ammatory cyto-
kines (TNFα, IFNγ, IL-6, IL-1β, and IL-12), chemokines 
(RANTES [regulated on activation, normal T cell expressed 
and secreted] and MIP-2), and NO, in serum (systemic) and 
in various target organs, including peritoneum, liver, lung, 
and intestine (Fig. 5). In addition, cortistatin administration 
Figure 2.  Treatment with cortistatin protects against lethal endo-
toxemia. (A–C) BALB/c mice were injected i.p. with different doses of LPS 
(control). Cortistatin (2 nmol/mouse) was injected i.p. 30 min after LPS 
administration. Survival was monitored during the next 96 h. Similar re-
sults were obtained in three identical independent experiments or when 
C57BL/6 mice were used. Mortality curves in B were used lo calculate 
LD50, and horizontal bars indicate the 95% confi  dence limits of LD50 deter-
minations. (C) The average survival time was calculated for nonsurvivors 
in both the untreated and cortistatin-treated groups. (D) Mice were 
injected i.p. with 400 μg LPS and different doses of cortistatin (from 0 to 
5 nmol/animal). (E) Mice were injected i.p. with 400 μg LPS and, 30 min 
later, treated with medium (control), cortistatin, somatostatin, octreotide 
or cyclosomatostatin (2 nmol/mouse). Survival was monitored during the 
next 96 h. (F) Cortistatin (2 nmol/mouse) was injected i.p. 2 or 4 h after 
LPS challenge. n = 12–20 mice/group. *, P < 0.001 versus untreated 
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increased the systemic and local levels of the antiinfl  amma-
tory cytokine IL-10 (Fig. 5), which has been shown to be 
protective in endotoxic shock (13).
Coagulation abnormalities, especially disseminated intra-
vascular coagulation and microthrombosis, are common fea-
tures during sepsis (1–4, 14). Acute phase proteins (APPs) are 
involved in the initiation of aberrant coagulation during en-
dotoxic shock (14). Cortistatin dramatically decreased the 
systemic levels of serum amyloid A (SAA) during septic 
shock (Fig. 5 B).
Cortistatin deactivates peritoneal macrophages 
during endotoxemia
The cortistatin-induced decrease in the levels of infl  amma-
tory factors in the target organs could result from the reduc-
tion in infl  ammatory cell infi  ltration. However, the fact that 
cortistatin down-regulates the in vitro production of various 
infl  ammatory factors by activated macrophages (Fig. 1) ar-
gues against this hypothesis. We determined the capacity of 
peritoneal macrophages isolated from untreated or cortistatin-
treated endotoxemic mice to produce infl  ammatory media-
tors ex vivo. Although macrophages from mice with septic 
shock produced spontaneously high amounts of TNFα, IL-6, 
IL-12, RANTES, and MIP-2, macrophages isolated from 
cortistatin-treated animals produced signifi  cantly lower levels 
of proinfl  ammatory cytokines and secreted high amounts of 
IL-10 (Fig. 6). Therefore, it is possible that the deactivation 
of resident and infi  ltrating macrophages is the major mecha-
nism in the antiinfl  ammatory action of cortistatin.
The combined therapy of cortistatin and other 
antiinfl  ammatory neuropeptides protects against 
lethal endotoxemia
We next evaluated the eff  ect of the combined treatment with 
cortistatin and another endogenous antiinfl  ammatory peptide 
(15), the vasoactive intestinal peptide (VIP). Administration 
of cortistatin together with VIP signifi  cantly prevented the le-
thality (50% survival) induced by a high dose of LPS (600 μg/
mouse), compared with mice treated with cortistatin or 
VIP alone that did not survive (Fig. 7, left). In addition, this 
Figure 3.  Cortistatin treatment reduces histopathologic signs of 
endotoxemia. Mice were injected i.p. with LPS (control). Cortistatin 
(2 nmol/mouse) was administered i.p. 30 min after LPS administration. 
(A) Cortistatin reduces infl  ammatory infi  ltration and disseminated coagu-
lation in target organs. Histopathology analysis was determined in hema-
toxylin and eosin–stained sections of lung and liver obtained at 24 h of 
disease. Bar, 100 μm. (B) Cortistatin decreases MPO activity in lung, liver, 
and intestine. MPO content was determined at different times after LPS 
infusion. (C) Cortistatin reduces leukocyte recruitment in the peritoneal 
cavity. Peritoneal cell suspensions were obtained at different times after 
LPS injection, and numbers of macrophages, lymphocytes, and PMNs were 
determined by fl  ow cytometry. n = 8–12 mice/group. *, P < 0.001 versus 
untreated control mice.
Figure 4.  Cortistatin protects against other types of experimental 
sepsis. (A) Sepsis was induced in C57BL/6 mice after cecal ligation and 
puncture (CLP). 2 nmol cortistatin was administered i.p. twice at 6-h 
  intervals beginning 4 h after CLP procedure. Survival was monitored over 
the next 8 d. n = 10 mice/group. *, P < 0.001 versus untreated control 
mice. (B) Endotoxemia was induced in BALB/c mice after i.p. injection of 
E. coli (108 cells), and medium (control) or 2 nmol cortistatin was adminis-
tered i.p. 2 h later. n = 8 mice/group. *, P < 0.001 versus untreated 
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  combined treatment permits to reduce the eff  ective thera-
peutic dose to 0.5 nmol cortistatin (Fig. 7, right). The syner-
gistic eff  ect of VIP and cortistatin in endotoxic shock could 
be the result of eff  ects on diff  erent cells or to the involve-
ment of diff  erent signal transduction pathways in the same 
target cell. We favor the latter because activated macro-
phages are the major players in the antiinfl  ammatory activity 
of both peptides, and VIP acts through cAMP-dependent 
pathways (16), whereas the cortistatin eff  ect should be cAMP 
independent (9).
D  I  S  C  U  S  S  I  O  N 
Septic shock is a life-threatening complication of infections 
and the most common cause of death in intensive care units 
(750,000 cases per year in the United States with a mortality 
rate of 30%). Although our understanding of the pathogenesis 
of infl  ammation and sepsis has improved, until recently this 
has not translated into clinical benefi  t. The current strategies 
for human septic shock therapy are derived mainly from ob-
servations made in animal models. Promising experimental 
results prompted large-scale randomized clinical trials with a 
variety of agents, such as antiendotoxin monoclonal anti-
bodies, glucocorticoids, or ibuprofen for nonspecifi  c down-
regulation of infl  ammation, IL-1 receptor antagonists, or 
anti-TNFα antibodies (3, 4). Unfortunately, despite some 
promising results during the preliminary trials, all the major 
clinical studies of immunomodulators in sepsis were disap-
pointing (17). There are several reasons for this lack of   success. 
In animal models, the cascade of events starting with the ini-
tial stimulus, resulting in a cytokine cascade and leading to 
death follows a predictable time course. Thus, experimental 
protocols designed to block one cytokine cascade or another 
are relatively straightforward. However, in the human septic 
shock syndrome, the sequence of events is more complex, 
Figure 5.  Treatment with cortistatin reduces local and systemic 
infl  ammatory responses in endotoxemic mice. Endotoxemia was in-
duced by i.p. injection of LPS (400 μg/mouse). Mice were treated 30 min 
later with medium (controls) or with cortistatin (2 nmol/mouse). Serum (A), 
peritoneal fl  uid (B), and protein extracts from lung, liver, and small 
intestine (C) were collected at various time points after endotoxin injec-
tion, and the cytokine/chemokine, NO, and SAA contents were determined 
as described in Materials and methods. n = 5–8 mice/group. *, P < 0.001 
versus untreated control mice.568  THERAPEUTIC EFFECT OF CORTISTATIN ON ENDOTOXEMIA | Gonzalez-Rey et al.
and the course of the disease generally lasts days rather than 
hours, as in most animal models. Therefore, because of the 
complex pathophysiology of sepsis, consideration should be 
given to multidrug therapy, similar to the approach taken in 
AIDS and cancer therapy. The present work proposes a new 
therapy for endotoxemia based on the use of the newly dis-
covered somatostatin-related peptide cortistatin. The admin-
istration of cortistatin protected against endotoxin-induced 
lethality. In addition, administration of cortistatin improved 
survival in two “true infection” models closer to sepsis in hu-
mans, such as cecal ligation and puncture and E. coli injection. 
Cortistatin prevented the septic shock-associated histopa-
thology, including infl  ammatory cell infi  ltration and multiorgan 
intravascular disseminated coagulation. The therapeutic eff  ect 
of cortistatin seems to be mediated through the decrease in 
the local and systemic levels of a wide spectrum of infl  amma-
tory mediators, including cytokines (TNFα, IL-6, IL-1β, 
IFNγ, and IL-12), chemokines (MIP-2 and RANTES) and 
acute phase proteins. The fact that the inhibitory eff  ects of 
cortistatin on the release of infl  ammatory mediators in vitro 
by peritoneal macrophages resembled closely the cytokine 
profi  le in mice treated with cortistatin suggests that the deac-
tivation of resident and infi  ltrating macrophages could be the 
major mechanism involved in the antiinfl  ammatory action of 
cortistatin. However, because cortistatin receptors are ubiqui-
tously expressed by monocytes/macrophages, dendritic cells, 
neutrophils, and endothelial cells (7–9), the participation of 
cells other than macrophages cannot be ruled out.
Among the proinfl  ammatory cytokines involved in endo-
toxic shock, TNFα appears to play a central role. Indeed, in-
creased serum TNFα levels appear during endotoxemia and 
TNFα injection induces shock, tissue damage, and death 
(18). During endotoxic shock, TNFα shows a spectrum of 
harmful eff  ects. These infects include enhanced procoagulant 
activity of vascular endothelial cells, activation of neutrophils 
and macrophages, and increase in combination with IFNγ in 
the expression of adherent molecules resulting in increased 
neutrophil/monocyte adherence to endothelial cells and tis-
sue infi  ltration. Lung and liver injury during endotoxemia is 
largely mediated through neutrophil and macrophage accu-
mulation (19). The excessive production of free radicals by 
activated macrophages and neutrophils results in tissue damage. 
The decrease in NO serum levels in cortistatin-treated mice 
is benefi  cial because NO mediates hypotension and cyto-
toxicity, two pathologic hallmarks of septic shock (1–4). In 
  addition, TNFα, IL-1β, and IL-6 aff  ect hepatocytes by mod-
ifying their metabolic pathway toward gluconeogenesis and 
aminoacid uptake, as well as increased synthesis of coagula-
tion and complement factors and of APPs. APPs are antipro-
teolitic enzymes that contribute to the procoagulant state 
and to the inhibition of fi  brinolysis observed in sepsis. During 
septic shock, there is an increase in the so-called positive 
APPs (α1-antitrypsin, α2-macroglobulin, serum amyloid A, 
fi  brinogen, and C-reactive protein), a decrease in negative 
APPs (protein C and antithrombin), and an increase in the 
thrombin-activated fi  brinolytic inhibitor (14). Coagulation 
abnormalities, especially disseminated intravascular coagula-
tion and microthrombosis, are common in patients with sep-
sis (1–4, 14). In our study, cortistatin dramatically decreased 
the systemic levels of the positive APP SAA during septic 
Figure 6.  Cortistatin treatment deactivates peritoneal macro-
phages during endotoxemia. Mice were injected i.p. with LPS (control) 
and treated i.p. with cortistatin (2 nmol/mouse) 30 min later. Peritoneal 
macrophages were isolated 8 h after LPS injection and cultured with 
  medium alone. After 48 h of culture, the concentration of infl  ammatory 
mediators in the culture supernatants was determined by ELISA 
(n = 5–6). *, P < 0.001 versus untreated control mice.
Figure 7.  Combined therapy of cortistatin and other antiinfl  am-
matory neuropeptides protects against lethal endotoxemia. Septic 
shock was induced by i.p. injection of LPS (600 or 400 μg/mouse). Mice 
were treated 30 min later with medium (controls) or with various combi-
nations of the neuropeptides (NP), cortistatin (CST), and vasoactive intes-
tinal peptide (VIP) (2 or 0.5 nmol/mouse). Survival was monitored during 
96 h. n = 8–10 mice/group. *, P < 0.001 versus mice treated with 
  cortistatin or VIP alone.JEM VOL. 203, March 20, 2006  569
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shock. This correlates with the fact that animals treated with 
cortistatin did not exhibit disseminated coagulation in any of 
the organs studied. The fact that cortistatin reduced local and 
systemic levels of the chemokines MIP-2 (chemotactic for 
neutrophils) and RANTES (chemotactic for macrophages/
monocytes) partially explains the absence of infl  ammatory 
  infi  ltrates in the aff  ected organs.
TNFα is at the pinnacle of a cascade of infl  ammatory 
mediators. During septic shock, TNFα precedes other pro-
infl  ammatory cytokines (Fig. 5), and the administration of 
anti-TNFα antibodies reduces the levels of IL-6 and IFNγ 
in endotoxemic animals (20, 21). This suggests that IL-6 and 
IFNγ are downstream of TNFα in the cytokine cascade in-
volved in septic shock, and that their production is dependent 
on TNFα. However, this conclusion is still under debate at 
least for IL-6. Thus, a specifi  c inhibitor for TNFα was shown 
to reduce TNFα, but not IL-6 levels after lethal endotoxin 
challenge (22). In patients with septic shock, IL-6 appears 
to be a better predictor for survival because higher plasma 
levels of IL-6, but not TNFα, are evident in the nonsurvivor 
group (23). The importance of infl  ammatory cytokines other 
than TNFα in the pathogenesis of the endotoxic shock is also 
indicated by the fact that pretreatment with corresponding 
neutralizing antibodies protects against lethality (21, 24–26). 
Therefore, the regulation by cortistatin of a wide range of 
infl  ammatory mediators at both the local and systemic level, 
including mediators that appear later during the infl  amma-
tory response, might off  er a therapeutic advantage over cur-
rent therapies using neutralizing antibodies directed against a 
single mediator. This also explains the protective eff  ect of de-
layed cortistatin administration in established endotoxemia.
Cortistatin shares many structural and functional prop-
erties with somatostatin. The lack of a signifi  cant phenotype 
in mice lacking a functional somatostatin gene (27) suggests 
a cortistatin compensatory eff   ect. However, the proposed 
compensatory role of cortistatin is brought into question by 
the lack of an increase in cortistatin gene expression in the 
somatostatin KO mice (27). Cortistatin and somatostatin ex-
hibit several distinct functions in the nervous system (5, 6). 
We fi  nd similar diff  erences in our system. Somatostatin and 
octreotide, a somatostatin analogue already introduced in the 
clinical practice, deactivate some macrophage populations 
and are protective in certain infl  ammatory disorders, such as 
pancreatitis and liver injury (9, 28, 29). However, they are 
not protective in lethal septic shock (Fig. 2 E and references 
9, 30). The superior potency of cortistatin in reducing in-
fl   ammation as compared with somatostatin and octreotide 
might reside in the capacity of cortistatin to activate diff  erent 
receptors and transduction pathways. Although somatostatin 
and octreotide only bind to somatostatin receptors, cortistatin 
can bind to other receptors as well. This is supported by 
the fact that the somatostatin receptor antagonist cycloso-
matostatin completely reversed the antiinfl  ammatory eff  ect of 
somatostatin and octreotide in vitro, whereas only partially 
reversing the eff  ect of cortistatin. Ghrelin is a new orexigenic 
hormone recently identifi   ed as a potent antiinfl  ammatory 
factor with therapeutic action in several infl  ammatory disor-
ders (11, 12, 31), and cortistatin, but not somatostatin or oc-
treotide, binds to the ghrelin receptor. In fact, a ghrelin 
receptor antagonist partially reversed the inhibitory eff  ect of 
cortistatin on cytokine production by macrophages (unpub-
lished data). Therefore, the possibility exists that cortistatin 
exerts its therapeutic eff  ect in septic shock, at least partially, 
through ghrelin receptors or cortistatin-specifi  c receptors not 
yet identifi  ed.
Of physiological relevance is the observation that the ex-
pression of cortistatin and its receptors increases in infl  amma-
tory cells in response to immune activation, especially after 
infl  ammatory stimuli (7, 8). Although the levels of cortistatin 
have not been yet measured in patients with sepsis, it is 
tempting to speculate that the body responds to an exacer-
bated infl   ammatory response by increasing the peripheral 
production of endogenous antiinfl  ammatory factors, includ-
ing cortistatin, in an attempt to restore homeostasis. Although 
cortistatin aff  ects cortical and locomotor activities and sleep 
induction in the central nervous system, we did not observe 
any adverse eff  ects of cortistatin in the concentration range 
used in our experimental system. Extending the use of cor-
tistatin to human patients will depend on the dosage. The 
ability of delayed administration of cortistatin to ameliorate 
ongoing disease also fulfi  lls an essential prerequisite for an 
  antiendotoxemic agent, as treatment starts after the onset of 
sepsis. In summary, this work identifi  es cortistatin as a new 
immunomodulatory factor with the capacity to deactivate 
the infl  ammatory response. Cortistatin might represent a 
multistep therapeutic agent for human septic shock for use in 
combination with other immunomodulatory agents or com-
plementary to other nonimmunomodulatory therapies.
MATERIALS AND METHODS
Induction of endotoxemia and study design. To induce endotoxemia, 
BALB/c and C57BL/6 mice (6–8 wk old; The Jackson Laboratory) were 
injected i.p. with diff  erent amounts (25–600 μg/mouse; 400 μg/mouse 
  unless otherwise indicated) of LPS (from Salmonella enteridis; Sigma-Aldrich). 
Animals were treated i.p. with medium (controls) or with diff  erent concen-
trations (0.05–5.0 nmol/mouse; 6–550 μg/kg) of cortistatin 1–29 (American 
Peptides Company), somatostatin, octreotide, or cyclosomatostatin (Sigma-
Aldrich) 30 min after challenge with LPS. To study the therapeutic eff  ect of 
delayed administration of cortistatin on established endotoxemia, cortistatin 
(2 nmol/mouse) was injected i.p. 2 or 4 h after endotoxin administration. 
Animals were monitored daily for survival and other clinical signs including 
ruffl   ed fur, lethargy, appearance of diarrhea, and body weight loss. Some 
  animals were killed at diff  erent times after LPS injection, blood samples were 
collected by cardiac puncture, peritoneal exudates were obtained as previ-
ously described (15), and liver, lungs, and small intestine were collected. The 
blood samples were allowed to clot for 1 h at room temperature and serum 
was obtained after centrifugation for determination of cytokines, chemo-
kines, and SAA. Tissue specimens were immediately frozen in liquid nitro-
gen for histological studies, protein extraction and cytokine determination, 
and MPO activity measurement. The peritoneal suspension was centrifuged 
for 5 min at 1,800 g, and cell-free supernatants (peritoneal fl  uid) were har-
vested and assayed for cytokine/chemokine production. Peritoneal cells were 
counted and adjusted in PBS/3 mM EDTA medium at 3 × 106 cells/ml. 
The number of viable cells in the diff  erent peritoneal subpopulations was 
determined by fl  ow cytometry (FACScan; BD Biosciences). In brief, perito-
neal lymphocytes, macrophages, and PMNs were gated according to their 570  THERAPEUTIC EFFECT OF CORTISTATIN ON ENDOTOXEMIA | Gonzalez-Rey et al.
diff  erent forward scatter and side scatter characteristics and counted. The 
large predominance of neutrophils (99%) in the PMN population was con-
fi  rmed in cytospin preparations stained with May-Grunwald and Giemsa. 
For histopathologic evaluation, freshly collected liver, lung, and intestine 
were fi  xed in 10% buff  ered formalin phosphate, embedded in sucrose, frozen 
in dry ice using OCT compound, and cryosectioned. Cross sections were 
stained with hematoxylin/eosin using standard techniques.
Alternatively, sepsis was induced by CLP. In brief, C57BL/6 mice were 
anesthetized with ketamine (75 mg/kg, intramuscular injection) and xyla-
zine (20 mg/kg, intramuscular injection) and a small abdominal midline inci-
sion was made. The cecum was exposed, mobilized, and ligated below the 
ileocecal valve and punctured through both surfaces twice with a 22-gauge 
needle and the stool was extruded (1 mm). The cecum was then placed back 
into its normal intra-abdominal position and the abdomen was closed with a 
running suture of 6–0 prolene. All animals received subcutaneous resuscita-
tive normal saline (20 ml/kg body weight) 4 h after surgery. Medium (controls) 
or cortistatin (2 nmol) were administered i.p. twice at 6-h intervals   beginning 
4 h after CLP. Survival was monitored once daily for 10 d.
For other sepsis model, BALB/c mice were injected i.p. with bacterial 
suspension containing 108 live E. coli cells (DH5-α; Invitrogen). 2 nmol cor-
tistatin was administered i.p. 2 h after E. coli injection.
All experiments were performed according to the Institutional Guide-
lines for the Care and Use of Laboratory Animals in Research and the ap-
proval of the local committee in the Consejo Superior de Investigaciones 
Cientifi  cas.
Cytokine, SAA, and nitric oxide determination. For cytokine deter-
mination in tissues, protein extracts were isolated by homogenization of 
lung, liver, and small intestine pieces (50 mg tissue/ml) in 50 mM Tris-HCl, 
pH 7.4, with 0.5 mM DTT, and 10 μg/ml of a cocktail of proteinase inhib-
itors containing phenylmethylsulfonyl fl   uoride, pepstatin, and leupeptin 
(Sigma-Aldrich). Samples were centrifuged at 30,000 g for 20 min and stored 
at −80°C until cytokine determination. Cytokine and chemokine levels in 
the serum, tissue protein extracts and culture supernatants were determined 
by a specifi  c sandwich ELISA by using capture/biotinylated detection Abs 
obtained from BD Biosciences and Peprotech according to the manufacturer’s 
recommendations. SAA levels were determined in serum samples by a 
murine ELISA kit (Tridelta Development). The amount of NO formed was 
estimated from the accumulation of the stable NO metabolite nitrite by the 
Griess assay. Before the Griess reaction, all nitrate was converted to nitrite 
using 5% vanadium trichloride. Equal volumes of culture supernatants (90 μl) 
and Griess reagents (90 μl of 1% sulfanilamide/0.1% N-[naphthyl]ethyl-
  enediamine dihydrochloride in 2.5% H3PO4) were mixed, and the absor-
bance was measured at 550 nm. The amount of nitrite was calculated from 
a NaNO2 standard curve.
MPO assay. Neutrophil infi  ltration in the lung, liver, and small intestine 
was monitored by measuring MPO activity by using a method reported pre-
viously (32). In brief, tissue specimens were homogenized at 50 mg/ml in 
phosphate buff  er (50 mM, pH 6.0) with 0.5% hexadecyltrimethylammo-
nium bromide. Samples were frozen, thawed three times, and centrifuged at 
30,000 g for 20 min. The supernatants were diluted 1:30 with assay buff  er con-
sisting in 50 mM phosphate buff  er pH 6.0 with 0.167 mg/ml o-dianisidine 
(Sigma-Aldrich) and 0.0005% H2O2, and the colorimetric reaction was 
measured at 450 nm between 1 and 3 min in a spectrophotometer (Beckman 
Instruments). MPO activity per gram of wet tissue was calculated as: MPO 
activity (U/g wet tissue) = (A450) (13.5)/tissue weight (g), where A450 is the 
change in the absorbance of 450nm light from 1 to 3 min after the initiation 
of the reaction. The coeffi   cient 13.5 was empirically determined such that 
1 U MPO activity is the amount of enzyme that will reduce 1 μmol 
peroxide/min.
Macrophage cultures. Resident macrophages were obtained by peritoneal 
lavage with RPMI 1640 medium. Peritoneal cells were washed in cold me-
dium and incubated in complete medium (RPMI 1640 supplemented with 
100 U/ml penicillin/streptomycin, 2 mM l-glutamine, 50 μM 2-mercapto-
ethanol, and 10% heat-inactivated fetal calf serum) at a concentration of 106 
cells/ml. After 2 h at 37°C, nonadherent cells were removed by extensive 
washing. At least 95% of the adherent cells were macrophages as judged by 
morphological and phagocytic criteria and by fl  ow cytometry. Macrophage 
monolayers were incubated with complete medium in the absence (un-
stimulated) or presence of LPS (1 μg/ml, from E. coli serotype 055:B5; 
Sigma-Aldrich). In some experiments, cortistatin, somatostatin, or octreotide 
(Sigma-Aldrich) were added at diff  erent concentrations (from 10−7 to 10−12 M) 
at the initiation of the culture, in the absence or presence of the somato-
statin antagonist cyclosomatostatin (Sigma-Aldrich). Cell-free supernatants were 
collected at diff  erent times and cytokine/chemokine levels were determined 
as described in the Cytokine, SAA, and nitric oxide determination section.
Data analysis. All values are expressed as mean ± SD of mice/experiment. 
The diff  erences between groups were analyzed by Mann-Whitney U test 
and, if appropriate, by Kruskal-Wallis analysis of variance test. Survival 
curves were analyzed by the Kaplan-Meyer log-rank test.
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